Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism MARCKS inhibitors(Myristoylated alanine-rich C-kinase substrate inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC40H63N11O14 |
InChIKeyYVHRIXZPNVBUTN-QZJYGJSKSA-N |
CAS Registry901117-44-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lung Injury | Preclinical | US | 15 Jul 2014 | |
Respiratory Distress Syndrome, Adult | Preclinical | US | - |